$SNDX
Syndax Pharmaceuticals Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023058165 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.78M $17.30M
YoY Change 123.5% 109.95%
% of Gross Profit
Research & Development $55.13M $39.09M
YoY Change 73.13% 45.3%
% of Gross Profit
Depreciation & Amortization $3.000K $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $77.91M $56.36M
YoY Change 85.34% 60.37%
Operating Profit -$56.36M
YoY Change 60.37%
Interest Expense $5.487M $70.00K
YoY Change 86.32% -96.0%
% of Operating Profit
Other Income/Expense, Net -$55.00K $5.209M
YoY Change -48.11% -2088.17%
Pretax Income -$72.47M -$51.10M
YoY Change 84.91% 44.34%
Income Tax
% Of Pretax Income
Net Earnings -$72.47M -$51.15M
YoY Change 84.91% 44.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.73
Diluted Earnings Per Share -$1.00 -$0.73
COMMON SHARES
Basic Shares Outstanding 69.64M 69.48M
Diluted Shares Outstanding 69.86M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $577.6M $373.8M
YoY Change 19.24% 6.58%
Cash & Equivalents $295.4M $94.55M
Short-Term Investments $282.2M $279.3M
Other Short-Term Assets $2.066M $3.000M
YoY Change 55.11% 51.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $580.9M $381.0M
YoY Change 18.6% 6.53%
LONG-TERM ASSETS
Property, Plant & Equipment $8.000K $10.00K
YoY Change -60.0% -56.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.83M $15.70M
YoY Change 445.42%
Other Assets $463.0K $587.0K
YoY Change -42.63% -33.37%
Total Long-Term Assets $32.00M $18.25M
YoY Change 329.58% 787.65%
TOTAL ASSETS
Total Short-Term Assets $580.9M $381.0M
Total Long-Term Assets $32.00M $18.25M
Total Assets $612.9M $399.2M
YoY Change 23.26% 10.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.961M $6.049M
YoY Change 128.99% -14.98%
Accrued Expenses $40.89M $33.10M
YoY Change 65.48% 141.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $12.00K $0.00
YoY Change 140.0% -100.0%
Total Short-Term Liabilities $58.10M $39.17M
YoY Change 99.88% 88.31%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $0.00
YoY Change -23.08% -100.0%
Other Long-Term Liabilities $578.0K $900.0K
YoY Change -18.48% 17.19%
Total Long-Term Liabilities $588.0K $864.0K
YoY Change -18.56% 10.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.10M $39.17M
Total Long-Term Liabilities $588.0K $864.0K
Total Liabilities $58.68M $40.04M
YoY Change 97.01% 85.49%
SHAREHOLDERS EQUITY
Retained Earnings -$902.4M -$829.9M
YoY Change 30.21% 26.93%
Common Stock $1.456B $1.190B
YoY Change 25.41% 19.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $554.2M $359.2M
YoY Change
Total Liabilities & Shareholders Equity $612.9M $399.2M
YoY Change 23.26% 10.99%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$72.47M -$51.15M
YoY Change 84.91% 44.47%
Depreciation, Depletion And Amortization $3.000K $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$41.35M -$44.65M
YoY Change 80.61% 56.43%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$16.29M $40.08M
YoY Change -88.16% -690.02%
Cash From Investing Activities -$16.29M $40.08M
YoY Change -88.16% -690.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 258.5M 1.850M
YoY Change 58.09% -113.68%
NET CHANGE
Cash From Operating Activities -41.35M -44.65M
Cash From Investing Activities -16.29M 40.08M
Cash From Financing Activities 258.5M 1.850M
Net Change In Cash 200.8M -2.720M
YoY Change 6641.99% -94.43%
FREE CASH FLOW
Cash From Operating Activities -$41.35M -$44.65M
Capital Expenditures $0.00
Free Cash Flow -$41.35M
YoY Change 80.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001395937
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37708
dei Entity Registrant Name
EntityRegistrantName
Syndax Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
419-1400
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SNDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69640668
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94550000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74356000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
269006000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
401446000
CY2023Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
10265000
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
8595000
CY2023Q3 sndx Collaboration Receivable
CollaborationReceivable
3407000
CY2022Q4 sndx Collaboration Receivable
CollaborationReceivable
3474000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3746000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1915000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
380974000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
489786000
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
15705000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
5469000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1731000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1039000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
217000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
115000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
587000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
807000
CY2023Q3 us-gaap Assets
Assets
399224000
CY2022Q4 us-gaap Assets
Assets
497236000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6049000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4350000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32119000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24276000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
995000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
434000
CY2023Q3 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
11000
CY2022Q4 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
5000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39174000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29065000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
709000
CY2023Q3 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
13000
CY2022Q4 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
13000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
864000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
722000
CY2023Q3 us-gaap Liabilities
Liabilities
40038000
CY2022Q4 us-gaap Liabilities
Liabilities
29787000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69638168
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69638168
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68111385
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68111385
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1189561000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1161288000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-455000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-806000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-829927000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-693040000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
359186000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
399224000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497236000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39087000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26901000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107906000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86658000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17268000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8240000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44143000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23066000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
56355000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
35141000
us-gaap Operating Expenses
OperatingExpenses
152049000
us-gaap Operating Expenses
OperatingExpenses
109724000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-56355000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35141000
us-gaap Operating Income Loss
OperatingIncomeLoss
-152049000
us-gaap Operating Income Loss
OperatingIncomeLoss
-109724000
CY2023Q3 us-gaap Interest Expense
InterestExpense
70000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1748000
us-gaap Interest Expense
InterestExpense
145000
us-gaap Interest Expense
InterestExpense
3094000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5345000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1781000
us-gaap Investment Income Interest
InvestmentIncomeInterest
15613000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2884000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-295000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-306000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-210000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5209000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
262000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15162000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-420000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-51146000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
us-gaap Net Income Loss
NetIncomeLoss
-136887000
us-gaap Net Income Loss
NetIncomeLoss
-110144000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
119000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
351000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1650000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51027000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35673000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136536000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111794000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51146000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35403000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-136887000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110144000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69855766
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69855766
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60670294
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60670294
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69645888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69645888
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59941384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59941384
us-gaap Profit Loss
ProfitLoss
-136887000
us-gaap Profit Loss
ProfitLoss
-110144000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
9000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
30000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11344000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1357000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
496000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
309000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
1103000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
187000
us-gaap Share Based Compensation
ShareBasedCompensation
22624000
us-gaap Share Based Compensation
ShareBasedCompensation
11778000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3281000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7674000
sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
68000
sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
-4539000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1699000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1445000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7364000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1545000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119252000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110781000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
225316000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
244467000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
359215000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
195683000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
225000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
133899000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48559000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
633000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
260000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5016000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10063000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19427000
us-gaap Payments For Proceeds From Deposit On Loan
PaymentsForProceedsFromDepositOnLoan
0
us-gaap Payments For Proceeds From Deposit On Loan
PaymentsForProceedsFromDepositOnLoan
20998000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5649000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8752000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20296000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-150588000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74471000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222080000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94767000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71492000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
2059000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> segment. References in these notes to condensed consolidated financial statements to “Syndax,” “the Company,” “we,” “us” or “our” refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-51146000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
us-gaap Net Income Loss
NetIncomeLoss
-136887000
us-gaap Net Income Loss
NetIncomeLoss
-110144000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51146000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-51146000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35403000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35403000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-136887000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-136887000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110144000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-110144000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69855766
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69855766
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60670294
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60670294
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69645888
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69645888
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59941384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59941384
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
285166000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
455000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
284711000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
422581000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
806000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
421775000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1336000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
692000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
788000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
583000
CY2023Q3 sndx Prepaid Subscriptions
PrepaidSubscriptions
1027000
CY2022Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
446000
CY2023Q3 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
318000
CY2022Q4 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
3000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
277000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
191000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3746000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1915000
CY2023Q3 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
21832000
CY2022Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
14375000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7931000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5945000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1588000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1352000
CY2023Q3 sndx Accrued Milestone Costs
AccruedMilestoneCosts
0
CY2022Q4 sndx Accrued Milestone Costs
AccruedMilestoneCosts
2000000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
768000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
604000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32119000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24276000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8321000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4362000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22624000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11778000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8321000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4362000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22624000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11778000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
628253
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1167295
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10100000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6238000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
470000
CY2023Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
196000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
435505000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8065000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-238000
CY2023Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
179000
CY2023Q2 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
-1000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1146000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44615000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
400041000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8321000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
119000
CY2023Q3 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
259000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1592000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-51146000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
359186000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3478000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-685000
CY2022Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
92000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
374549000
CY2022Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
19427000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2022Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
58000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2235000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
361940000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4362000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
CY2022Q3 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
110000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7363000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
338102000
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3802144
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81200000
CY2023Q2 sndx Number Of Pre Funded Warrants Exercised For Common Stock
NumberOfPreFundedWarrantsExercisedForCommonStock
273000
CY2023Q2 sndx Number Of Pre Funded Warrants Exercised For Common Stock
NumberOfPreFundedWarrantsExercisedForCommonStock
498137
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7840909
CY2022Q4 sndx Offering Price Per Share
OfferingPricePerShare
22
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162000000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
sndx-20230930_cal.xml Edgar Link unprocessable
0000950170-23-058165-index-headers.html Edgar Link pending
0000950170-23-058165-index.html Edgar Link pending
0000950170-23-058165.txt Edgar Link pending
0000950170-23-058165-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20230930.htm Edgar Link pending
sndx-20230930.xsd Edgar Link pending
sndx-ex31_1.htm Edgar Link pending
sndx-ex31_2.htm Edgar Link pending
sndx-ex32_1.htm Edgar Link pending
sndx-20230930_def.xml Edgar Link unprocessable
sndx-20230930_lab.xml Edgar Link unprocessable
sndx-20230930_pre.xml Edgar Link unprocessable
sndx-20230930_htm.xml Edgar Link completed